US Rx Drug Sales For 1996 Up 10% At $85.35 Billion

24 February 1997

In 1996, US prescription pharmaceutical sales to pharmacies rose 10% tohit $85.35 billion, according to figures from IMS America, which noted that topping the list were antiulcer products and antidepressants.

The best-selling US prescription drug, with $1.76 billion in sales, was again Glaxo Wellcome's Zantac (ranitidine). Just behind this in the number two spot was Astra-Merck's antiulcerant Prilosec (omeprazole), with $1.74 billion in turnover, and in third place was Lilly's Prozac (fluoxetine) at $1.69 billion.

Sales of Amgen's Epogen (epoetin alfa) rose 23% to $1.18 billion, while those of Pfizer's Zoloft (sertraline) reached $1.1 billion last year, according to IMS figures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight